Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Director/PDMR Shareholding

3 Feb 2009 09:41

RNS Number : 6924M
PuriCore Plc
03 February 2009
 



Directors' Dealings

 PuriCore Directors Acquire Shares in the Company

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 3 February 2009 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announces that on 2 February 2009 the following Directors purchased shares in the Company, as set out below:

Name

Number of shares purchased

Purchase Price of shares

Total number of shares held

% of issued share capital

Director

James Walsh

180,000

5.125p

500,000

.23%

Joseph William Birkett

440,000

5.500p

540,000

.25%

Enquiries:

Ben Brewerton 

Greg Bosch, CEO

Susan Quigley

Darren Weiss, VP, Finance

Financial Dynamics

PuriCore

+44 (0) 20 7831 3113

+1 484 321 2700

About PuriCore

PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisationThe Company's products are used in a broad range of markets that depend upon controlling contamination, including retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of M. tuberculosis, MRSA, E.coli, Norovirus, H5N1 Avian Influenza, HIV, Salmonella, Polio Virus, Helicobater pylori, and Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK. 

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUUUUCPUPBUBW
Date   Source Headline
26th Mar 20197:00 amRNSCancellation of AIM Listing
25th Mar 20194:40 pmRNSSecond Price Monitoring Extn
25th Mar 20194:35 pmRNSPrice Monitoring Extension
20th Mar 201911:12 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
18th Mar 201910:31 amRNSForm 8.5 (EPT/RI) Earthport Plc
18th Mar 201910:30 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
15th Mar 20192:35 pmRNSResult of General Meeting
15th Mar 201910:09 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
14th Mar 201911:01 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
13th Mar 201910:48 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
12th Mar 201911:53 amRNSForm 8.3 - Realm Therapeutics PLC
12th Mar 201910:07 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
11th Mar 201910:30 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
8th Mar 201911:30 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
7th Mar 201911:16 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
6th Mar 20199:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
5th Mar 20199:32 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
4th Mar 201911:41 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
1st Mar 201910:07 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
28th Feb 201911:14 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
27th Feb 20194:58 pmRNSForm 8.3 - Realm Therapeutics
27th Feb 20194:41 pmRNSSecond Price Monitoring Extn
27th Feb 20194:36 pmRNSPrice Monitoring Extension
27th Feb 201911:01 amGNWInvesco Ltd.: Form 8.3 - Realm Therapeutics PLC
26th Feb 201910:01 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
25th Feb 201910:08 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
22nd Feb 201911:36 amGNWInvesco Ltd.: Form 8.3 - Realm Therapeutics PLC
22nd Feb 201910:02 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
21st Feb 20194:34 pmRNSForm 8.3 - Realm Therapeutics plc
21st Feb 20194:26 pmRNSHolding(s) in Company
21st Feb 20194:26 pmRNSHolding(s) in Company
21st Feb 201912:36 pmGNWInvesco Ltd.: Form 8.3 - Realm Therapeutics Plc
21st Feb 20199:59 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Feb 201910:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
19th Feb 20192:05 pmRNSSecond Price Monitoring Extn
19th Feb 20192:00 pmRNSPrice Monitoring Extension
19th Feb 20199:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
18th Feb 20199:25 amRNSForm 8.5 (EPT/RI)Realm Therapeutics
18th Feb 20199:05 amRNSSecond Price Monitoring Extn
18th Feb 20199:00 amRNSPrice Monitoring Extension
18th Feb 20197:00 amRNSBlock listing Interim Review
18th Feb 20197:00 amRNSUpdate on Strategic Review Re-release
15th Feb 20196:20 pmRNSUpdate on Strategic Review
15th Feb 20199:22 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
13th Feb 201910:01 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
11th Feb 201910:01 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
7th Feb 20199:48 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
6th Feb 201910:48 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
5th Feb 20199:26 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
4th Feb 201911:23 amRNSForm 8.5 (EPT/RI) Realm Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.